Perkin Elmer has introduced Lutetium-177 nuclide, a GMP-compliant radiochemical solution for nuclear medicine centres and pharmaceutical companies developing targeted cancer therapies.
Lu-177 can be used to investigate more than 30 different clinical applications including targets for the treatment of colon cancer, metastatic bone cancer, non-Hodgkin's lymphoma and lung cancer.
The manufacturing of Good Manufacturing Practice (GMP) compliant Lu-177 supports companies that are taking active steps to develop radiopharmaceutical solutions to create potential 'smart drugs' for targeted cancer therapies.
Recently, Perkin Elmer and the University of Missouri Research Reactor entered into a collaborative agreement to upgrade the production of Lu-177 from radiochemical grade to achieve compliance with ICH Q7 GMP Guidance for Active Pharmaceutical Ingredients, August.
The company said Lu-177 has features and benefits including: low-energy gamma rays for investigating diagnostic imaging and radiotherapy; short tissue-penetration path length for investigating targeted therapy of small tumours; relatively long half-life of 6.71 days; custom dispensed for added flexibility and convenience.
